A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

• ClinicalTrials.gov Identifier: NCT03549000
• Recruitment Status: Terminated
• First Posted: June 7, 2018
• Last Update Posted: October 18, 2023
• Sponsor: Novartis Pharmaceuticals
• Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )

Study Description

Brief Summary:

The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

Condition or disease	Intervention/treatment	Phase
Non-small Cell Lung Cancer (NSCLC); Triple Negative Breast Cancer (TNBC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer Microsatellite Stable (MSS); Ovarian Cancer; Renal Cell Carcinoma (RCC); Metastatic Castration Resistant Prostate Cancer (mCRPC)	Other: NZV930; Other: PDR001; Drug: NIR178	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 127 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.
• Actual Study Start Date: July 18, 2018
• Actual Primary Completion Date: October 17, 2022
• Actual Study Completion Date: October 17, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: NZV930 Monotherapy; Single Agent NZV930	Other: NZV930; NZV930, Specified dose on specified days, intravenous (IV); Other Name: Biological
Experimental: NZV930 with PDR001 Doublet Therapy; Combination of NZV930 with PDR001	Other: NZV930; NZV930, Specified dose on specified days, intravenous (IV); Other Name: Biological; Other: PDR001; PDR001, Specified dose on specified days, intravenous (IV); Other Name: Biological
Experimental: NZV930 with NIR178 Doublet Therapy; Combination of NZV930 with NIR178	Other: NZV930; NZV930, Specified dose on specified days, intravenous (IV); Other Name: Biological; Drug: NIR178; NIR178 Specified dose on specified days, Orally
Experimental: NZV930 with NIR178 & PDR001 Triplet Therapy; Combination of NZV930 with NIR178 and PDR001	Other: NZV930; NZV930, Specified dose on specified days, intravenous (IV); Other Name: Biological; Other: PDR001; PDR001, Specified dose on specified days, intravenous (IV); Other Name: Biological; Drug: NIR178; NIR178 Specified dose on specified days, Orally

Outcome Measures

Primary Outcome Measures :

1. Number of participants with adverse events as a measure of safety and tolerability of the NZV930 in combination with PDR001 and/or NIR178 [ Time Frame: 3 years ]
   Incidence and severity of AEs and SAEs, incl. changes in laboratory parameters, vital signs, and ECGs Dose limiting toxicity in cycle 1 (28 days) for single agent NZV930 and NZV930 in combination with PDR001 and/or NIR178 during dose escalation phase only Tolerability: dose interruptions Tolerability: dose reductions Tolerability: dose intensity

Secondary Outcome Measures :

1. Overall response rate (ORR) [ Time Frame: 3 years ]
   Defined as the proportion of patients with best overall response of CR or PR
2. Clinical Benefit Rate (CBR) [ Time Frame: 3 years ]
   Defined as the proportion of patients with best overall response of CR, PR or SD >= 16 weeks
3. Progression Free Survival (PFS) [ Time Frame: 3 years ]
   Defined as the time from the date of start of treatment to the date of the event defined as first documented progression or death due to any cause
4. Serum concentration vs. time profiles of NZV930 (free drug) and PDR001. [ Time Frame: 3 years ]
   Serum concentration vs. time profiles of NZV930 (free drug) and PDR001.
5. Plasma concentration vs. time profiles for NIR178 and derived PK parameters [ Time Frame: 3 years ]
   Concentration time profile of NIR178 and its metabolites
6. To assess the immunogenicity of NZV930 and PDR001 [ Time Frame: 3 years ]
   Presence and titer of anti-drug antibodies, anti-NZV930 and anti-PDR001 in (patients receiving combination with PDR001).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Adult men & women ≥ 18 years of age Histologically confirmed advanced malignancies with documented progression following standard therapy, or for whom, in the opinion of the investigator, no appropriate standard therapy exists.

Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. The patient must be willing to undergo a new tumor biopsy at screening and during treatment.

ECOG performance status 0-2 and in the opinion of the investigator, likely to complete at least 56 days of treatment.

Exclusion Criteria:

Symptomatic or uncontrolled Brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids.

Patients with treated symptomatic brain metastases should be neurologically stable for 4 weeks post-treatment prior to study entry and at doses of <10 mg per day prednisolone or equivalent for at least 2 weeks before administration of any study treatment.

Patients who required discontinuation of treatment due to treatment-related toxicities with prior immunotherapy.

Patients previously treated with anti-CD73 treatment and/or adenosine receptor A2a (A2aR) inhibitors.

Active, previously documented, or suspected autoimmune disease within the past 2 years.

Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur should not be excluded. Additionally, patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.

History of or current drug-induced interstitial lung disease or pneumonitis grade ≥ 2.

Impaired cardiovascular function or clinically significant cardiovascular disease, including any of the following: Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA Grade ≥ 2), uncontrolled hypertension or clinically significant arrhythmia Patients with corrected QT using the Fridericia's correction (QTcF) > 470 msec for females or >450 msec for males, on screening ECG or congenital long QT syndrome Acute myocardial infarction or unstable angina < 3 months prior to study entry History of stroke or transient ischemic event requiring medical therapy Symptomatic claudication Infection: HIV infection, Active HBV or HCV infection (per institutional guidelines). Patients with chronic HBV or HCV disease that is controlled under antiviral therapy are allowed in the expansion but not in the escalation, Known history of tuberculosis Infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed treatment before screening is initiated.

Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, 6 weeks is indicated as washout period. For patients receiving anticancer immunotherapies, 4 weeks is indicated as the washout period.

Systemic chronic steroid therapy (≥ 10 mg/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, nasal, and ophthalmic steroids are allowed

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations

Locations

United States, Florida

H Lee Moffitt Cancer Center and Research Institute Inc

Tampa, Florida, United States, 33612

United States, Texas

University of Texas MD Anderson Cancer Center MD Anderson PSC

Houston, Texas, United States, 77030

Australia, Victoria

Novartis Investigative Site

Melbourne, Victoria, Australia, 3000

Canada, Ontario

Novartis Investigative Site

Toronto, Ontario, Canada, M5G 1Z6

Canada, Quebec

Novartis Investigative Site

Montreal, Quebec, Canada, H2W 1T8

Japan

Novartis Investigative Site

Chuo ku, Tokyo, Japan, 104 0045

Singapore

Novartis Investigative Site

Singapore, Singapore, 169610

Spain

Novartis Investigative Site

Valencia, Comunidad Valenciana, Spain, 46010

Novartis Investigative Site

Madrid, Spain, 28009

United Kingdom

Novartis Investigative Site

Sutton, Surrey, United Kingdom, SM2 5PT

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

• Study Director: Novartis Pharmaceuticals; Novartis Pharmaceuticals

More Information

Additional Information:

Study Results 

• Responsible Party: Novartis Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT03549000
• Other Study ID Numbers: CNZV930X2101; 2018-000153-51 ( EudraCT Number )
• First Posted: June 7, 2018
• Last Update Posted: October 18, 2023
• Last Verified: October 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

NZV930; PDR001; NIR178; Immune checkpoint inhibitor; immunotherapy; CD73; PD-1; PD-L1; A2aR; Adenosine

Additional relevant MeSH terms:

Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Urogenital Diseases; Male Urogenital Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Kidney Neoplasms; Urologic Neoplasms; Kidney Diseases; Urologic Diseases; Breast Neoplasms; Breast Diseases; Skin Diseases; Spartalizumab; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents, Immunological; Antineoplastic Agents